An agreement has been reached to allow the distribution of a low-cost, long-acting form of HIV vaccine in low-income countries where most of the world’s diseases occur, Unitaid and the United Patent Pool announced on Thursday.
The deal will see ViiV Healthcare, a subsidiary of pharmaceutical giant GSK, allow selected manufacturers to produce generic versions of Cabotegravir LA, which is long-acting. pre-exposure prophylaxis (PrEP) HIV treatment.
The agreement will allow the injectable form of Cabotegravir, which has been shown to provide two months of protection against infection, in 90 countries where more than 70 percent of new HIV infections are happen in 2020, said Unitaid.
“Providing effective HIV prevention options can significantly contribute to the goal of ending HIV transmission and ending the epidemic by 2030,” said Unitaid spokesperson Herve Verhoosel.
“Efforts to increase access to Cabotegravir LA for PrEP would be very effective for groups with high rates of infection, such as men who have sex with men and sex workers,” he said.
The news comes a day after a new report presented at the International Conference on AIDS in Montreal, Canada, which shows that the fight against AIDS in the world has stalled due to the collapse of resources due to COVID-19 and other conflicts.
Some 1.5 million new infections occurred last year – more than a million more than the world’s fight against the disease.
A long-acting version of Cabotegravir has recently become available, and has been shown to be more effective than the oral version that needs to be taken every day.
But the cost—a year’s worth of treatment reached $22,000 in the United States earlier this year—has been a barrier to widespread use in all developing countries.
Unitaid is an international health program that works to ensure equal access to new medical procedures in low- and middle-income countries.
The Medicines Pool, established by Unitaid with the support of the United Nations, works to license medicines needed for general distribution internationally. middle income countries.
© 2022 AFP
hint: Consensus reached for HIV prevention (2022, July 28) Retrieved July 28, 2022 from https://medicalxpress.com/news/2022-07-drug-hiv-infection.html
This document is subject to copyright. Except for any bona fide transaction for research or investigation purposes, no part may be reproduced without written permission. Content is provided for informational purposes only.
Deal reached for generic drug to prevent HIV infection Source link Deal reached for generic drug to prevent HIV infection